Is a decline in estimated GFR an appropriate surrogate end point for renoprotection drug trials?

Kidney International

Volumn 85, Issue 4, 2014, Pages 723-727

  Rosansky, Steven J ^a   Glassock, Richard J ^b  

^a WJB Dorn VA Medical Center   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; AST 120; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; BIOLOGICAL MARKER;

BLOOD PRESSURE REGULATION; CARDIOVASCULAR MORTALITY; CHRONIC KIDNEY DISEASE; DIET RESTRICTION; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY PERFUSION; MACROALBUMINURIA; MUSCLE ATROPHY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN INTAKE; RENAL FUNCTION TRAJECTORY; RENAL PROTECTION; RENAL REPLACEMENT THERAPY; RENAL SYSTEM PARAMETERS; REVIEW; RISK ASSESSMENT; RISK FACTOR; BIOASSAY; DRUG THERAPY; KIDNEY FAILURE, CHRONIC; RANDOMIZED CONTROLLED TRIAL (TOPIC); ALBUMINURIA; CAUSE OF DEATH; DISEASE ASSOCIATION; DRUG EFFECT; DRUG SCREENING; DRUG TREATMENT FAILURE; END STAGE RENAL DISEASE; KIDNEY CLEARANCE; PROTEIN RESTRICTION; SURVIVAL RATE;

BIOLOGICAL MARKERS; DRUG THERAPY; ENDPOINT DETERMINATION; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY FAILURE, CHRONIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84897384640     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2013.506     Document Type: Editorial

References (31)

1. Earlier endpoints proposed for chronic kidney disease trials. Nephrol News Issues 5 December 2012.
2. Stevens LA, Greene T, Levey AS. Surrogate end points for clinical trials of kidney disease progression. Clin J Am Soc Nephrol 2006; 1: 874-884.
3. Rosansky SJ, Clark WF, Eggers P et al. Initiation of dialysis at higher GFRs: Is the apparent rising tide of early dialysis harmful or helpful?. Kidney Int 2009; 76: 257-261.
4. Cravedi P, Ruggenenti P, Remuzzi G. Proteinuria should be used as a surrogate in CKD. Nat Rev Nephrol 2012; 8: 301-306.
5. Remuzzi G, Benigni A, Remuzzi A. Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes. J Clin Invest 2006; 116: 288-296.
6. Formentini I, Bobadilla M, Haefliger C et al. Current drug development challenges in chronic kidney disease (CKD)-identification of individualized determinants of renal progression and premature cardiovascular disease (CVD). Nephrol Dial Transplant 2012; 27(Suppl 3): Iii81-iii88.
7. Beddhu S, Samore MH, Roberts MS et al. Creatinine production, nutrition, and glomerular filtration rate estimation. J Am Soc Nephrol 2003; 14: 1000-1005.
8. Grootendorst DC, Michels MW, Richardson JD et al. The MDRD formula does not reflect GFR in ESRD patients. Nephrol Dial Transplant 2011; 26: 1932-1937.
9. Li L, Astor BC, Lewis J et al. Longitudinal progression trajectory of GFR among patients with CKD. Am J Kidney Dis 2012; 59: 504-512.
10. Hu B, Gadegbeku C, Lipkowitz MS et al. Kidney function can improve in patients with hypertensive CKD. J Am Soc Nephrol 2012; 23: 706-713.
11. Perkins RM, Bacaloiu ID, Kirchner HL et al. GFR decline and mortality risk among patients with chronic kidney disease. Clin J Am Soc Nephrol 2011; 6: 1879-1886.
12. Chapter 2: Definition, identification, and prediction of CKD progression. Kidney Disease: Improving Global Outcomes. Kidney Int Suppl 2013; 3: 63-72.
13. Turin TC, Hemmelgarn BR. Change in kidney function over time and risk for adverse outcomes: Is an increasing estimated GFR harmful?. Clin J Am Soc Nephrol 2011; 6: 1805-1806.
14. Turin TC, Coresh J, Tonelli M et al. Change in the estimated glomerular filtration rate over time and risk of all-cause mortality. Kidney Int 2013; 83: 684-691.
15. Pergola PE, Raskin P, Toto RD et al. Bardoxolone methyl and kidney function in CKD with type 2 diabetes. N Engl J Med 2011; 365: 327-336.
16. Schulman G, Agarwal R, Acharya M et al. A multicenter, randomized, double-blind, placebo-controlled, doseranging study of AST-120 (Kremezin) in patients with moderate to severe CKD. Am J Kidney Dis 2006; 47: 565-577.
17. Schulman G, Berl T, Beck G et al. EPPIC (Evaluating Prevention of Progression In Chronic Kidney Disease): Results from 2 phase III, randomized, placebo-controlled, double-blind trials of AST-120 in adults with CKD. MIU-12-0785 ASN Abstract-EPPIC-FINAL-091212, Kidney Week 2012. www. asn-online.org.
18. Ambrogi V, Thilly N, Boini S et al. Patterns and predictors of kidney function decline in the last year prior to dialysis. Nephron Clin Pract 2009; 111: C95-c101.
19. Lorenzo V, Saracho R, Zamora J et al. Similar renal decline in diabetic and non-diabetic patients with comparable levels of albuminuria. Nephrol Dial Transplant 2010; 25: 835-841.
20. Gaspari F, Ruggenenti P, Porrini E et al. The GFR and GFR decline cannot be accurately estimated in type 2 diabetics. Kidney Int 2013; 84: 164-173.
21. Ruggenenti P, Gaspari F, Cannata A et al. Measuring and estimating GFR and treatment effect in ADPKD patients: Results and implications of a longitudinal cohort study. GFRADPKD Study Group. PLoS One [online] 2012; 7: E32533.
22. Rosansky SJ. Renal function trajectory is more important than chronic kidney disease stage for managing patients with chronic kidney disease. Am J Nephrol 2012; 36: 1-10.
23. Chapter 3: Management of progression and complications of CKD. Kidney Disease: Improving Global Outcomes. Kidney Int Suppl 2013; 3: 73-90.
24. Rule AD, Glassock RJ. GFR estimating equations: Getting closer to the truth?. Clin J Am Soc Nephrol 2013; 8: 1414-1420.
25. Hsu C-Y, Propert K, Xie D et al. Measured GFR does not outperform estimated GFR in predicting CKD-related complications. J Am Soc Nephrol 2011; 22: 1931-1937.
26. Lemley KV, Boothroyd DB, Blouch KL et al. Modeling GFR trajectories in diabetic nephropathy. Am J Physiol Renal Physiol 2005; 289: F863-F870.
27. Juraschek SP, Appel LJ, Anderson CA et al. Effect of a highprotein diet on kidney function in healthy adults: Results from the OmniHeart trial. Am J Kidney Dis 2013; 61: 547-554.
28. Hofstra JM, Willems JL, Wetzels JF. Estimated glomerular filtration rate in the nephrotic syndrome. Nephrol Dial Transplant 2011; 26: 550-556.
29. Padala S, Tighiouart H, Inker LA et al. Accuracy of a GFR estimating equation over time in people with a wide range of kidney function. Am J Kidney Dis 2012; 60: 217-224.
30. Lewis J, Greene T, Appel L et al. A comparison of iothalamate-GFR and serum creatinine-based outcomes: Acceleration in the rate of GFR decline in the African-American Study of Kidney Disease and Hypertension. J Am Soc Nephrol 2004; 15: 3175-3183.
31. Grams ME, Coresh J, Segev DL et al. Vascular disease, ESRD, and death: Interpreting competing risk analyses. Clin J Am Soc Nephrol 2012; 7: 1606-1614.